# The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis

Study · id `cardio:ct-nct03471065` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03471065](<https://clinicaltrials.gov/study/NCT03471065>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03471065

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03471065. Allocation not applicable; no masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2019-12-23 (actual). Results posted on 2021-01-19.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03471065, source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)
- Started: 2018-06-01 (actual) (ClinicalTrials.gov record NCT03471065, source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)
- Primary completion: 2019-12-23 (actual) (ClinicalTrials.gov record NCT03471065, source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)
- Completion: 2025-01-21 (actual) (ClinicalTrials.gov record NCT03471065, source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)
- Results first posted: 2021-01-19 (ClinicalTrials.gov record NCT03471065, source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)
- Countries: Canada; United Kingdom (ClinicalTrials.gov record NCT03471065, source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03471065-2025-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis
- Condition: Aortic Valve Stenosis
- Intervention (Device): SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: 7a98837d5417455a6d834ef9b31dd93a90fb94e13250d22020253c9ca2debb7d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
